Analysts Set Crispr Therapeutics AG (CRSP) PT at $58.55

Shares of Crispr Therapeutics AG (NASDAQ:CRSP) have been assigned an average rating of “Buy” from the sixteen ratings firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and ten have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $58.55.

CRSP has been the subject of several analyst reports. BidaskClub cut Crispr Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, October 5th. Guggenheim initiated coverage on Crispr Therapeutics in a report on Tuesday, October 9th. They issued a “neutral” rating for the company. Raymond James initiated coverage on Crispr Therapeutics in a report on Thursday, September 20th. They issued an “underperform” rating for the company. Wells Fargo & Co initiated coverage on Crispr Therapeutics in a report on Wednesday, October 10th. They issued an “outperform” rating and a $65.00 target price for the company. Finally, Needham & Company LLC initiated coverage on Crispr Therapeutics in a report on Friday, November 30th. They issued a “buy” rating and a $62.00 target price for the company.

In other news, President Rodger Novak sold 17,310 shares of the stock in a transaction on Tuesday, January 8th. The stock was sold at an average price of $35.09, for a total transaction of $607,407.90. Following the completion of the transaction, the president now directly owns 1,130,697 shares in the company, valued at approximately $39,676,157.73. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Vertex Pharmaceuticals (Europe purchased 90,742 shares of the stock in a transaction dated Monday, December 24th. The shares were acquired at an average price of $24.08 per share, with a total value of $2,185,067.36. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 153,682 shares of company stock valued at $3,700,718. Company insiders own 37.70% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp raised its holdings in shares of Crispr Therapeutics by 42.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 31,104 shares of the company’s stock valued at $1,827,000 after purchasing an additional 9,326 shares during the period. BlackRock Inc. grew its stake in Crispr Therapeutics by 3.7% in the 2nd quarter. BlackRock Inc. now owns 593,527 shares of the company’s stock valued at $34,876,000 after buying an additional 21,309 shares during the last quarter. PNC Financial Services Group Inc. acquired a new position in Crispr Therapeutics in the 2nd quarter valued at about $581,000. FMR LLC acquired a new position in Crispr Therapeutics in the 2nd quarter valued at about $11,629,000. Finally, Renaissance Technologies LLC acquired a new position in Crispr Therapeutics in the 2nd quarter valued at about $10,054,000. Institutional investors own 43.83% of the company’s stock.

NASDAQ CRSP opened at $35.40 on Monday. Crispr Therapeutics has a one year low of $22.22 and a one year high of $73.90. The firm has a market capitalization of $1.84 billion, a P/E ratio of -20.70 and a beta of 3.48.

Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Thursday, November 8th. The company reported ($1.07) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.74) by ($0.33). Crispr Therapeutics had a negative net margin of 331.84% and a negative return on equity of 40.41%. The firm had revenue of $0.56 million during the quarter, compared to analyst estimates of $2.64 million. During the same period in the prior year, the company posted ($0.62) earnings per share. The firm’s revenue for the quarter was down 76.6% compared to the same quarter last year. Equities analysts predict that Crispr Therapeutics will post -3.26 earnings per share for the current year.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, which targets sickle cell disease and beta-thalassemia with an ex vivo approach whereby cells are harvested from a patient, treated with a CRISPR/Cas9-based therapeutic and reintroduced into the patient.

See Also: What is a Reverse Stock Split?

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit